[HTML][HTML] Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma
Oncotarget, 2016•ncbi.nlm.nih.gov
Background Pancreatic ductal adenocarcinoma (PDAC) is one of the most common cancer
death reasons. Anti-tumor necrosis factor-alpha (TNF-α) antibodies have shown promising
effects in PDAC pre-clinical models. However, the prognostic values of TNF-α, underlying
mechanisms by which anti-TNF-α treatments inhibit PDAC, and potential synergistic effects
of anti-TNF-α treatments with chemotherapy are still unclear.
death reasons. Anti-tumor necrosis factor-alpha (TNF-α) antibodies have shown promising
effects in PDAC pre-clinical models. However, the prognostic values of TNF-α, underlying
mechanisms by which anti-TNF-α treatments inhibit PDAC, and potential synergistic effects
of anti-TNF-α treatments with chemotherapy are still unclear.
Abstract
Background
Pancreatic ductal adenocarcinoma (PDAC) is one of the most common cancer death reasons. Anti-tumor necrosis factor-alpha (TNF-α) antibodies have shown promising effects in PDAC pre-clinical models. However, the prognostic values of TNF-α, underlying mechanisms by which anti-TNF-α treatments inhibit PDAC, and potential synergistic effects of anti-TNF-α treatments with chemotherapy are still unclear.
ncbi.nlm.nih.gov
